SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2015
Prana Biotechnology Limited
(Name of Registrant)
Level 2, 369 Royal Parade Parkville Victoria 3052 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____
This Form 6-K is being incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-199783) and Form S-8 (File No. 333-153669).
PRANA BIOTECHNOLOGY LIMITED
6-K | Items |
1. | Prana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PRANA BIOTECHNOLOGY LIMITED | |||
(Registrant) | |||
By: | /s/ Geoffrey Kempler | ||
Geoffrey Kempler, | |||
Executive Chairman |
November 6, 2015
Prana Receives Non-Compliance Notice Regarding NASDAQ
Minimum Bid Price Requirement
MELBOURNE, Australia. 6 November, 2015: Prana Biotechnology Limited (ASX: PBT/NASDAQ:PRAN) has received notification from the Listing Qualifications Department of NASDAQ advising the Company that it is currently non-compliant with NASDAQ's requirement that listed securities maintain a minimum bid price of $US1.00 per share on NASDAQ as outlined in the NASDAQ Listing Rules.
The NASDAQ notification has no effect at this time on the listing of the Company's American Depositary Shares (“ADSs”) and the ADSs will continue to trade uninterrupted on NASDAQ under the symbol "PRAN". The Company’s ordinary shares which are traded on the Australian Securities Exchange (“ASX”) under the symbol “PBT” are in full compliance with ASX listing requirements and are completely independent of the NASDAQ listing. Prana’s management intends to actively monitor the bid price for its ADSs and will consider all available options to regain compliance with the NASDAQ minimum bid price requirement.
Prana has a compliance period of 180 calendar days (until May 2, 2016) to regain compliance with the minimum bid price requirement. If at any time during the 180 day compliance period, the closing bid price per ADS is at least $US1.00 for at least ten consecutive business days, NASDAQ will provide the Company a written confirmation of compliance and the matter will be closed.
In the event Prana does not regain compliance, the Company may be eligible for an additional 180 calendar days' extension to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The NASDAQ Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the NASDAQ staff concludes that the Company will not be able to cure the deficiency or if the Company is otherwise not eligible, the Company's ADSs will be subject to delisting by NASDAQ.
Contacts:
Investor Relations
Rebecca Wilson
E: rwilson@buchanwe.com.au
Tp: +61 3 8866 1205
1 |
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana’s technology.
For further information please visit the Company’s web site at www.pranabio.com
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.
2 |
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end
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end